ELEVATE

{ "short_title": "ELEVATE", "data_mode": "900", "data_mode_number": "000002371", "official_title": "A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of \r\nElacestrant in Various Combinations in Patients with Metastatic Breast \r\nCancer", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "adjuvant", "therapielinie_value": "second", "ctgov_number": "NCT05563220", "eudract_number": "2022-002609-10", "general_contact_email": "studiensekretariat.gyn@ukdd.de", "general_contact_phone": "+49 351-4584202", "hauptpruefer_dd_name": "Prof. Dr. med. Pauline Wimberger", "description_laie_de": "Eine offene Rahmenstudie der Phase 1b/2 zur Bewertung der Sicherheit und Wirksamkeit von Elacestrant in \r\nverschiedene Kombinationen bei Patientinnen mit metastasiertem Brustkrebs (ELEVATE)", "description_laie_en": "A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in \r\nVarious Combinations in Patients with Metastatic Breast Cancer (ELEVATE)", "description_expert_de": "Eine offene Rahmenstudie der Phase 1b/2 zur Bewertung der Sicherheit und Wirksamkeit von Elacestrant in \r\nverschiedene Kombinationen bei Patientinnen mit metastasiertem Brustkrebs (ELEVATE)", "description_expert_en": "A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in \r\nVarious Combinations in Patients with Metastatic Breast Cancer (ELEVATE)", "rechtsgrundlage_value": "AMG", "phase_amg_value": "I", "main_cat_id": 3, "sub_cat_id": 16 }